Drug Trial Radar · NCT06675929
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Jan 20, 2025
Primary completion
Jan 13, 2026
Study completion Jan 13, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of this study is to find out how well a medicine called BI 770371 is tolerated. Participants are put into 2 groups by chance. One group gets BI 770371 as an infusion into a vein and the other group gets placebo as an infusion into a vein. Placebo infusions look like BI 770371 infusions but do not contain any medicine. Participants get an infusion every 3 weeks for 12 weeks. Participants are in the study for about 5 months. During this time, they visit the study site 16 times. This also includes 1 overnight stay at the study site. The doctors regularly check participants' health and collect information on any health problems of the participants. The results are compared between the 2 groups.
Conditions
- Compensated Liver Cirrhosis
- Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions
BI 770371Drug
BI 770371
Placebo for BI 770371Drug
Placebo for BI 770371
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment-emergent, drug-related adverse events in the BI 770371 and placebo armsTime frame: Up to Week 15
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
The Institute for Liver Health II dba Arizona Clinical Trials
Chandler, Arizona
Southern California Research Center
Coronado, California
Catalina Research Institute, LLC-Montclair-49051
Montclair, California
Knowledge Research Center
Orange, California
Inland Empire Clinical Trials, LLC
Rialto, California
Peak Gastroenterology Associates-Colorado Springs-67762
Colorado Springs, Colorado
Evolution Clinical Trials
Miami, Florida
Blessed Health Care
Miami, Florida
Progressive Medical Research
Port Orange, Florida
The Liver Institute at Methodist Dallas
Dallas, Texas
Houston Research Institute
Houston, Texas
American Research Corporation at the Texas Liver Institute
San Antonio, Texas
Pinnacle Clinical Research, LLC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.